CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NYSE: CRL·Wilmington, Massachusetts·CIK 0001100682
- Price
- $335.52
- Base IV
- $95.23
Valuation snapshot
At $335.52, the price is above even our bull case of $146.85.
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $95.23
- 28% of the price · range $30.05–$146.85
- Price vs base case
- 252% above
- $335.52 against $95.23
- Base case · our researched forecast, 2026-11-11See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
The price has fallen 3.0% since this valuation was struck on 2026-11-11, so some of the gap opened up after these figures were set.
Whisker on the base case runs bear $30.05 to bull $146.85. Values per share.
Price against each value
- Bear case
- $30.05
- Price 1,016% above
- No growth
- …
- —
- Base case
- $95.23
- Price 252% above
What does Charles River Laboratories International do?
Charles River Laboratories provides pharmaceutical and biotechnology companies with outsourced drug discovery and development services, including laboratory testing and non-human primate research.
It brought in $4B of sales in the 12 months to Sep 2026.
Led by Birgit Girshick, Chief Executive Officer since 2026. Birgit Girshick — Management Biography
- Industry
- Healthcare
- Based in
- Wilmington, Massachusetts
- Trades on
- NYSE as CRL
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 1¢ was left as profit after every cost, interest and tax. The biggest cost is everything else it takes to operate, 78¢ of every dollar.
- Sales, marketing and admin18¢
- Everything else it takes to operate78¢
- Interest and other costs7¢
- Left as profit1¢
- Tax credit came back in+4¢
Who pays Charles River Laboratories International, and for what?
Charles River sells research animals, drug discovery and safety testing services, and products that help manufacturers check the quality of medicines. It earns revenue when customers buy those products or pay it to run research and testing.
Its customers are mainly pharmaceutical and biotechnology companies, alongside other businesses, hospitals, universities and government agencies.
Research Models and Services
21%Supplies research animals, related care and testing services, and human cells used in research.
Charles River CD-1® IGS mouseImage: Charles River Laboratories International Discovery and Safety Assessment
60%Helps customers discover potential drugs and test their safety before and during human trials.
Charles River Apollo® study-data portalImage: Charles River Laboratories Manufacturing Solutions
19%Provides contamination and quality testing for medicines. Its 2025 revenue also included cell and gene therapy manufacturing services.
Where its work physically happens, beyond headquarters:
- Mattawan Safety Assessment Campus — Mattawan, United States. The 1.1-million-square-foot facility conducts thousands of drug safety, bioanalytical, analytical, and medical device studies each year.
- Montreal Preclinical Facility — Montreal, Canada. This 530,000-square-foot facility provides toxicology, pharmacology, and laboratory services across the drug development process.
- Reno Safety Assessment Facility — Reno, United States. The 465,000-square-foot facility performs regulated toxicology and related studies for clients on the West Coast and in Asia.
- Charleston Microbial Solutions Facility — Charleston, United States. Its GMP facility manufactures Endosafe bacterial endotoxin testing reagents and cartridges used in pharmaceutical and medical device quality control.
- Ashland Preclinical Facility — Ashland, United States. The approximately 309,000-square-foot site provides toxicology, pathology, and laboratory services for preclinical development.
How is the business doing?
Sales grew from $2.9B in 2020 to $4B in 2025, about 7% a year.
Running the business leaves about 4¢ of each sales dollar as operating profit, down from 15¢ in 2020.
After paying for its upkeep and new investment, it had $399.6M of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
The company says its purpose is to help create healthier lives through its work supporting research and drug development.
“create healthier lives”
Who is responsible for the plan?
- Birgit GirshickChief Executive Officer
Leads Charles River Laboratories and its company-wide strategic priorities. Charles River sells research models, drug discovery and safety assessment services, and products and services supporting pharmaceutical manufacturing.
- Shannon M. ParisottoCorporate Executive Vice President, Global Discovery & Safety Assessment
Oversees the global Discovery and Safety Assessment businesses and their strategic and operational development. Her segment sells outsourced drug discovery, bioanalytical services, and safety testing and accounted for 59.8% of company revenue in 2025.
- Namandjé N. BumpusCorporate Senior Vice President, Chief Scientific & Innovation Officer
Leads scientific strategy, oversees research and development initiatives, and chairs the Scientific Advisory Board. Her scientific and innovation responsibilities support the drug development services Charles River provides to clients, including development and adoption of alternative testing methods.
Roles checked November 11, 2026.
What management says it is working on now:
Match capacity to demand
Management plans to close or combine about 12 more sites over two years, mainly in research models and drug discovery and safety testing.
2025 Form 10-K, Item 1Combine discovery and safety teams
The company is bringing these services into one organization with shared sales and scientific teams to make it easier for customers to use both.
2025 Form 10-K, Item 1Improve efficiency
Management is simplifying work, changing purchasing practices and combining support functions to lower costs while demand is subdued.
2025 Form 10-K, Item 7Strengthen scientific services
Management aims to expand testing and other capabilities that customers find costly to build themselves, including methods that may supplement animal studies.
2025 Form 10-K, Item 1
- Revenue growth excluding acquisitions, divestitures and currency changes, Fiscal 2026
- 0% to 1%
- Second-Quarter 2026 Results
- Annual cost savings from efficiency and restructuring actions, By the end of 2026
- About $300 million in cumulative savings at an annual rate
- 2025 Form 10-K, Item 7
What's changing right now?
Growth is holding steady. In Q3 2026 it sold 2% less than a year earlier. The year before, quarters averaged -1%.
Its operating margin is wider than a year ago: 21¢ per sales dollar, against 13¢.
Since Oct 2026 the share price has fallen 11%, from $376.10 to $335.52.
Recently
November 4, 2026
DSA quarterly net book-to-bill, retained portfolio changed to 1.09 number
Q3 presentation Q3 2026 retained-portfolio KPIDecember 28, 2024
Discovery and Safety Assessment Segment Revenue changed to $2.4B
Charles River Laboratories 2024 Form 10-K Segment NoteDecember 28, 2024
Consolidated Annual Capital Expenditures changed to $233.0M
Charles River Laboratories 2024 Form 10-K Statements of Cash Flows
Coming up
November 4, 2026
Third-quarter results
The next results and conference call may show whether the recent improvement in demand for drug discovery and safety testing continued.
Charles River Schedules Third-Quarter 2026 Earnings Release and Conference Call
Our own estimate moved too: the base case went from $105.26 to $95.23 a share between our last two valuations. The biggest reason: DSA quarterly net book-to-bill, retained portfolio moved from an unreported prior value to 1.09 number, as reported in Q3 presentation Q3 2026 retained-portfolio KPI.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Customers may delay research
Drug companies can reduce or postpone early research spending. Lower study volumes hurt discovery and safety assessment revenue in 2025.
From the company's own filingsWould hit how fast sales grow2025 Form 10-K, Items 1A and 7
Research contracts can shrink or end
Customers may cancel or reduce work with little notice. Fixed-price work can also cost more to perform than Charles River expected.
From the company's own filingsWould hit how much of each sale it keeps2025 Form 10-K, Item 1A
Limited animal supply
Some research offerings depend on a small number of suppliers, particularly for non-human primates. An interruption could limit studies and sales.
From the company's own filingsWould hit how fast sales grow2025 Form 10-K, Item 1A
Cost savings may fall short
Site closures and staffing changes may take longer or cost more than expected, reducing the savings management has planned.
From the company's own filingsWould hit how much of each sale it keeps2025 Form 10-K, Item 1A
Testing rules may change
Changes in drug testing requirements could reduce demand for some services or add compliance costs. Wider use of new research methods could reduce demand for some animal models.
From the company's own filingsWould hit how fast sales grow2025 Form 10-K, Item 1A
Customer data could be exposed
A security breach could interrupt studies, expose confidential customer information and lead to lost contracts or legal claims.
From the company's own filingsWould hit how fast sales grow2025 Form 10-K, Item 1A
RMS organic sales still declined in Q2, indicating an uneven recovery.
From our researchWould hit how fast sales growCRL Q2 2026 results
Q3 year-to-date depreciation was 121300000 against capital expenditure of 133823000, so existing net fixed-asset spending alone would imply much less reinvestment.
From our researchWould hit how much it has to reinvestCRL Q3 2026 Form 10-Q
Is it a good business?
From 2016 to 2025 it earned between 0% and 12% on the capital invested in it, a median of 9%. Its cost of capital in the latest valuation is 9.4%; returns were above it in 5 of the 10 years.
From 2016 to 2025 it earned between -5% and 18% on its shareholders' equity, a median of 15%.
Over 10 years its operating margin ranged from 1¢ to 17¢ per sales dollar, a median of 15¢. Gross margin ran from 37¢ to 38¢.
Cost of capital 9.4%
It bought back shares: the count fell 1.7% in a year, so each remaining share owns a slightly bigger slice.
It owes $2.2B more than it holds in cash, about 14.1 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $335.52. Our put its value between $30.05 and $146.85, with $95.23 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $30.05
After recent sales declines, the recovery fades and Charles River earns less from its laboratories while spending to keep them competitive.
Base case, $95.23
Following recent sales declines, testing demand gradually recovers and the sale of weaker businesses helps Charles River keep more of each sales dollar.
Bull case, $146.85
The recent improvement develops into a lasting recovery, with fuller laboratories and lower costs producing stronger sales and profits.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects far more than we do.Price above value: 252%
For Charles River Laboratories International to be worth today's $335.52, sales would need to grow about 29.3% a year. We assume 4.1%. Over the last 5 years, sales grew 3.0% a year.
Or, if sales grow 4.1% as we assume, the price works with a profit margin of 55.3% (we assume 20.5%).
Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.
Do you think sales can grow 29.3% a year?
Try your own numbersWe're not very sure of this range: it scores 45 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $95.23 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average4.1%
- Operating margin20.5%
- Long-term growth rate2.5%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$95.23 -71.6%


